Myeloproliferative neoplasms (MPNs), acute myeloid leukemia (AML) and clonal hematopoiesis of indeterminate potential (CHiP) are the focus of our research. These hematopoietic stem cell diseases represent a continuum (CHiP-MPN-AML), which explains that certain mutations are shared between these entities. This disease group represents an ideal model to study clonal evolution and identify factors that may drive transformation to a more severe disease.
Our laboratory uses patients-derived xenografts (PDX) to assess human hematopoietic stem and progenitor cell function and for the preclinical testing of candidate compounds (Theocharides et al., Haematologica 2016, Lysenko et al., Blood advances 2020). We use MISTRG mice which have been genetically engineered to express and produce human cytokines, which supports the development of human myeloid cells.